title: A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment.
abstract: BACKGROUND
  Colorectal cancer (CRC) is the predominant gastrointestinal malignancy and the leading cause of cancer death. The identification of genes related to CRC is important for the development of successful therapies and earlier diagnosis.
  
  
  METHODS
  Molecular analysis of feces was evaluated as a potential method for CRC detection. Expression of a predicted protein with unknown function, KIAA0247, was found in feces evaluated using specific quantitative real-time polymerase chain reaction. Its cellular function was then analyzed using immunofluorescent staining and the changes in the cell cycle in response to 5-fluorouracil (5-FU) were assessed.
  
  
  RESULTS
  Gastrointestinal tissues and peripheral blood lymphocytes ubiquitously expressed KIAA0247. 56 CRC patients fell into two group categories according to fecal KIAA0247 mRNA expression levels. The group with higher fecal KIAA0247 (n=22; ≥0.4897) had a significantly greater five-year overall survival rate than the group with lower fecal KIAA0247 (n = 30; <0.4897) (66.0 ± 11.6%; p=0.035, log-rank test). Fecal expression of KIAA0247 inversely related to CRC tumor size (Kendall's tau-b=-0.202; p=0.047). Immunofluorescent staining revealed that the cytoplasm of CRC cells evenly expresses KIAA0247 without 5-FU treatment, and KIAA0247 accumulates in the nucleus after 40 μM 5-FU treatment. In HCT116 p53(-/-) cells, which lack p53 cell cycle control, the proportion of cells in the G2/M phase was larger (13%) in KIAA0247-silent cells than in the respective shLuc control (10%) and KIAA0247-overexpressing cells (7%) after the addition of low dose (40 μM) 5-FU. Expression of three cyclin genes (cyclin A2, cyclin B1, and cyclin B2) also downregulated in the cells overexpressing KIAA0247.
  
  
  CONCLUSIONS
  This is the first description of a linkage between KIAA0247 and CRC. The study's data demonstrate overexpression of KIAA0247 associates with 5-FU therapeutic benefits, and also identify the clinical significance of fecal KIAA0247 in CRC.
authors: School of Medicine, Fu Jen Catholic University, New Taipei 24205, Taiwan.
authors: Chi-Jung
authors: CJ
authors: Huang
authors: Shung-Haur
authors: SH
authors: Yang
authors: Shih-Ming
authors: SM
authors: Huang
authors: Chih-Ming
authors: CM
authors: Lin
authors: Chih-Cheng
authors: CC
authors: Chien
authors: Yan-Chu
authors: YC
authors: Chen
authors: Chia-Long
authors: CL
authors: Lee
authors: Hao-Han
authors: HH
authors: Wu
authors: Chun-Chao
authors: CC
authors: Chang
references: Scand J Gastroenterol. 2005 Nov;40(11):1343-50
references: 16334444
references: BMC Cancer. 2010 Jul 15;10:370
references: 20630104
references: Mol Cancer. 2010 Apr 30;9:98
references: 20433755
references: Oncogene. 2009 Mar 12;28(10):1366-78
references: 19151762
references: Int J Oncol. 2003 Jan;22(1):51-7
references: 12469184
references: Gastroenterology. 2004 Aug;127(2):422-7
references: 15300574
references: Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8493-7
references: 7667317
references: Nat Rev Clin Oncol. 2010 Jun;7(6):318-25
references: 20440283
references: Oncogene. 1998 Feb 19;16(7):933-43
references: 9484785
references: J Lab Clin Med. 2003 Nov;142(5):306-12
references: 14647034
references: Cancer Res. 1999 Sep 15;59(18):4634-41
references: 10493518
references: Cancer Lett. 2005 Aug 8;226(1):55-63
references: 16004932
references: Anticancer Res. 1999 May-Jun;19(3A):1827-32
references: 10470122
references: Clin Cancer Res. 2002 Nov;8(11):3311-4
references: 12429616
references: Cell Div. 2007 Jul 19;2:22
references: 17640378
references: J Cell Mol Med. 2008 Oct;12(5B):1936-43
references: 18266979
references: Cancer Res. 2001 Sep 15;61(18):6660-4
references: 11559530
references: J Clin Oncol. 2003 Feb 1;21(3):395-6
references: 12560423
references: Cancer Res. 2007 Dec 1;67(23):11317-26
references: 18056458
references: Oncol Rep. 2006 Apr;15(4):919-26
references: 16525680
references: Clin Colorectal Cancer. 2006 Nov;6(4):265-72
references: 17241511
references: Genet Test Mol Biomarkers. 2010 Oct;14(5):703-8
references: 20854102
references: Gastroenterology. 2010 Jun;138(6):2115-26
references: 20167216
references: Cancer Biol Ther. 2010 Feb;9(3):246-52
references: 20023412
references: Cancer Res. 2005 Nov 15;65(22):10255-64
references: 16288013
references: Curr Med Chem. 2001 Oct;8(12):1487-503
references: 11562278
references: Lancet. 2010 Mar 20;375(9719):1030-47
references: 20304247
references: PLoS Genet. 2010 Feb 26;6(2):e1000863
references: 20195506
references: Cancer Res. 2001 Aug 1;61(15):5843-9
references: 11479224
references: Oncogene. 2001 Apr 5;20(15):1803-15
references: 11313928
references: J Cell Mol Med. 2007 Mar-Apr;11(2):252-85
references: 17488476
references: N Engl J Med. 1988 Sep 1;319(9):525-32
references: 2841597
references: BMC Cancer. 2009 Oct 22;9:376
references: 19849844
references: Cancer Metastasis Rev. 2010 Mar;29(1):181-206
references: 20135198
references: Mol Cell. 1997 Dec;1(1):3-11
references: 9659898
references: Mol Cancer. 2010 Sep 21;9:253
references: 20858281
references: J Clin Oncol. 2010 Sep 10;28(26):4052-7
references: 20644083